Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cannabidiol/tetrahydrocannabinol - Zelira Therapeutics

Next Previous
Drug Profile

Cannabidiol/tetrahydrocannabinol - Zelira Therapeutics

Alternative Names: CDB/THC; medicinal cannabis; Tetrahydrocannabinol/cannabidiol - Zelira Therapeutics; Zenivol; ZTL 101

Latest Information Update: 25 Jul 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zelira Therapeutics
  • Developer The University of Western Australia; Zelira Therapeutics
  • Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antidementias; Antiemetics; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Appetite stimulants; Cannabinoids; Chromans; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Non-opioid analgesics; Obesity therapies; Phytotherapies; Skin disorder therapies; Small molecules
  • Mechanism of Action 5-HT1 serotonin receptor modulators; Cannabinoid receptor agonists; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Insomnia

Most Recent Events

  • 21 Jul 2022 Registered for Insomnia in Germany (Sublingual) in July 2022
  • 21 Jul 2022 Zelira Therapeutics plans to launch cannabidiol/tetrahydrocannabinol in Germany for treatment of insomnia
  • 18 Jul 2022 Preregistration for Insomnia in Germany (Sublingual) prior to July 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top